Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1470-2045(20)30484-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy.
Am J Hematol
January 2025
Department I of Internal Medicine and Medical Faculty, University of Cologne, Köln, Germany.
Disease Overview: Chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia. It typically occurs in older patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that interfere with the regulation of proliferation and apoptosis in clonal B-cells.
View Article and Find Full Text PDFBackground: Patients with chronic lymphocytic leukemia (CLL) are susceptible to infections that can affect their clinical outcomes.
Aims: To assess: (1) the incidence of pneumonia in CLL patients treated with venetoclax-based regimens in a real-world setting, (2) the risk factors for event-free survival (EFS), and (3) overall survival (OS).
Methods: This multicenter study included 322 patients from eight centers.
The Impact of Targeted Therapies on Red Blood Cell Aggregation in Patients with Chronic Lymphocytic Leukemia Evaluated Using Software Image Flow Analysis.
Micromachines (Basel)
January 2025
Center of Competence at Mechatronics and Clean Technologies-MIRACle, "Acad. G. Bontchev" Str. 4, 1113 Sofia, Bulgaria.
Chronic lymphocytic leukemia (CLL), the most common type of leukemia, remains incurable with conventional therapy. Despite advances in therapies targeting Bruton's tyrosine kinase and anti-apoptotic protein BCL-2, little is known about their effect on red blood cell (RBC) aggregation in blood flow. In this study, we applied a microfluidic device and a newly developed Software Image Flow Analysis to assess the extent of RBC aggregation in CLL patients and to elucidate the hemorheological effects of the commonly applied therapeutics Obinutuzumab/Venetoclax and Ibrutinib.
View Article and Find Full Text PDFPneumonia in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens: A Real-World Analysis of the Polish Adult Leukemia Group (PALG).
Cancers (Basel)
December 2024
Clinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Background/objectives: Patients with chronic lymphocytic leukemia (CLL) are susceptible to infections that can affect their clinical outcomes.
Aims: The aims of this study were to assess the following: (1) the incidence of pneumonia in CLL patients treated with venetoclax-based regimens in a real-world setting, (2) the risk factors for event-free survival (EFS), and (3) overall survival (OS).
Methods: This multicenter study included 322 patients from eight centers.
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients.
Blood Cancer J
January 2025
Department of Immunology, Laboratory of Medical Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!